Insight

Michael Chuong: Excited That the Phase 3 NRG ONCOLOGY GI011 Trial in Locally Advanced Pancreatic Cancer Has Been Activated

Michael Chuong/mapquest.com

Jun 22, 2025, 10:33

Michael Chuong: Excited That the Phase 3 NRG ONCOLOGY GI011 Trial in Locally Advanced Pancreatic Cancer Has Been Activated

Michael Chuong, Vice Chair and Medical Director of the Department of Radiation Oncology at Miami Cancer Institute, shared a post on LinkedIn:

“I’m really excited that the phase 3 NRG ONCOLOGY GI011 trial (NCT06958328) has been activated, which randomizes patients with locally advanced pancreatic cancer after induction chemotherapy to ablative radiation therapy vs. standard of care chemotherapy/radiation therapy or observation.

The primary endpoint is 3-year OS, based off promising data including some from Baptist Health Miami Cancer Institute and Florida International University – Herbert Wertheim College of Medicine suggesting that ablative radiation therapy can meaningfully extend long-term OS.

This study has the potential to be paradigm changing as prior randomized trials using standard lower radiation doses did not improve OS for this disease over chemotherapy alone, so please support it at your institution!

Congrats to Nina Sanford and the entire study team – now let’s get to work!”

Read further.

GI011 Trial

More posts featuring Michael Chuong on OncoDaily.

Baptist Health Miami Cancer Institute cancer Florida International University Herbert Wertheim College of Medicine Miami Cancer Institute Michael Chuong NCT06958328 Nina Sanford NRG Oncology OncoDaily Oncology Pancreatic Cancer

Cancer in Dogs: Common Types, Symptoms, Diagnosis, and Treatment

Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?